Joseph Rosado
PhysicianJoseph Rosado, MD, LLC/DocMJDr. Joseph Rosado, MD, MBA, DC, EMT-P, CNA
Dr. Joseph Rosado is a physician executive, healthcare strategist, and nationally recognized expert in clinical governance for emerging cannabinoid and psychedelic therapeutics. His work bridges medicine, healthcare leadership, public policy, and industry to advance evidence-informed, physician-led models of care.
Over a career spanning emergency medical services, primary care, public health, behavioral medicine, and executive leadership, Dr. Rosado has served as Chief Medical Officer, Medical Director, physician executive, educator, and healthcare consultant across integrated health systems, federally qualified health centers, correctional medicine, and multi-site clinical organizations. His expertise includes clinical quality, physician leadership, regulatory compliance, patient safety, healthcare innovation, and system-wide quality improvement.
Dr. Rosado currently serves on the Board of Directors of the Indigenous Cannabis Industry Association (ICIA), is National Medical Director for Minorities for Medical Marijuana, and advises organizations developing responsible clinical frameworks for cannabinoid and psychedelic medicine. His work focuses on integrating physician oversight, clinical governance, precision medicine, artificial intelligence, outcomes measurement, and voluntary consensus standards into emerging therapeutic markets.
A frequent national and international speaker, Dr. Rosado is committed to ensuring that cannabis and psychedelic medicine evolve with the same scientific rigor, ethical standards, and patient protections expected throughout modern healthcare.
Precision Medicine and AI: Engineering the Next Era of Cannabis and Psychedelics Therapeutics
Cannabis and psychedelic therapeutics sit at a scientific inflection point. Clinical evidence is mounting for cannabinoids and compounds like psilocy
Cannabis and psychedelic therapeutics sit at a scientific inflection point. Clinical evidence is mounting for cannabinoids and compounds like psilocybin and MDMA across pain, treatment-resistant depression, PTSD, and neurological conditions. Yet the
Cannabis and psychedelic therapeutics sit at a scientific inflection point. Clinical evidence is mounting for cannabinoids and compounds like psilocybin and MDMA across pain, treatment-resistant depression, PTSD, and neurological conditions. Yet the field still struggles with a core problem: variability. Patient responses differ widely based on genetics, metabolism, the endocannabinoid system, and complex entourage effects, making standardized d
Cannabis and psychedelic therapeutics sit at a scientific inflection point. Clinical evidence is mounting for cannabinoids and compounds like psilocybin and MDMA across pain, treatment-resistant depression, PTSD, and neurological conditions. Yet the field still struggles with a core problem: variability. Patient responses differ widely based on genetics, metabolism, the endocannabinoid system, and complex entourage effects, making standardized dosing and reproducible outcomes difficult to achieve.
Precision medicine and artificial intelligence offer a path forward. Machine learning models can analyze pharmacogenomic data, real-world evidence, and multi-omic datasets to predict individual responses, refine dosing protocols, and stratify patients for trials. AI-driven phenotyping and biomarker discovery accelerate the move from anecdotal use toward defensible, evidence-based therapeutics.
This session unpacks the clinical and technological synergy reshaping the space. The panelists will examine algorithmic dosing models, predictive analytics in trial design, and the data infrastructure required to scale responsibly under evolving cannabis business compliance standards. Throughout, they’ll connect the science to current cannabis market trends and the commercial signals driving investment.
